Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Next Previous
Trial Profile

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorolanib (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms LUCIA
  • Sponsors EyePoint Pharmaceuticals

Most Recent Events

  • 06 Aug 2025 According to an EyePoint Pharmaceuticals media release, the company received approval of the Phase 3 protocols for the LUGANO and LUCIA trials by the European Medicines Agency (EMA).
  • 06 Aug 2025 According to an EyePoint Pharmaceuticals media release, this trial randomized over 400 patients in the U.S. and ex-U.S. sites over a seven-month period,Enrolled the first ex-U.S. patient in the LUCIA trial in Israel with patient participation in sites throughout the Czech Republic, South America, Europe, Australia and India.
  • 29 Jul 2025 According to an EyePoint Pharmaceuticals media release, LUGANO and LUCIA are supported by the robust safety and efficacy data from the DAVIO 2 Phase 2 clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top